Michael Adamzik

Michael Adamzik

Auto-generated profile, based on publicly available information

Michael Adamzik

Ruhr University Bochum, Knappschaft Kliniken Universitätsklinikum Bochum, Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätstraße 150, Bochum, Germany, 49 02343229242

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
GGGodwin Denk Giebel
Godwin Denk Giebel
PRPascal Raszke
Pascal Raszke
HNHartmuth Nowak
Hartmuth Nowak
LPLars Palmowski
Lars Palmowski
MAMichael Adamzik
Michael Adamzik
NBNikola Blase
Nikola Blase
Background: Digitalization is currently revolutionizing health care worldwide. A promising technology in this context is artificial intelligence (AI). The application of AI can support health care providers in their daily work in various ways. The integration of AI is particularly promising in clinical decision support systems (CDSSs). While the opportunities of this technology are numerous, the problems should not be overlooked. Objective: This study aimed to identify challenges and barriers in the context of AI-based CDSSs from the perspectives of experts across various disciplines. Methods: Semistructured expert interviews were conducted with different stakeholders. These included representatives of patients, physicians and caregivers, developers of AI-based CDSSs, researchers (studying AI in health care and social and health law), quality management and quality assurance representatives, a representative of an ethics committee, a representative of a health insurance fund, and medical product consultants. The interviews took place on the web and were recorded, transcribed, and subsequently subjected to a qualitative content analysis based on the method by Kuckartz. The analysis was conducted using MAXQDA software. Initially, the problems were separated into “general,” “development,” and “clinical use.” Finally, a workshop within the project consortium served to systematize the identified problems. Results: A total of 15 expert interviews were conducted, and 309 expert statements with reference to problems and barriers in the context of AI-based CDSSs were identified. These emerged in 7 problem categories: technology (46/309, 14.9%), data (59/309, 19.1%), user (102/309, 33%), studies (17/309, 5.5%), ethics (20/309, 6.5%), law (33/309, 10.7%), and general (32/309, 10.4%). The problem categories were further divided into problem areas, which in turn comprised the respective problems. Conclusions: A large number of problems and barriers were identified in the context of AI-based CDSSs. These can be systematized according to the point at which they occur (“general,” “development,” and “clinical use”) or according to the problem category (“technology,” “data,” “user,” “studies,” “ethics,” “law,” and “general”). The problems identified in this work should be further investigated. They can be used as a basis for deriving solutions to optimize development, acceptance, and use of AI-based CDSSs. International Registered Report Identifier (IRRID): RR2-10.2196/preprints.62704

7 July 2025 in JMIR Medical Informatics
Verified
Journal Article
Open access
GGGodwin Denk Giebel
Godwin Denk Giebel
PRPascal Raszke
Pascal Raszke
HNHartmuth Nowak
Hartmuth Nowak
LPLars Palmowski
Lars Palmowski
MAMichael Adamzik
Michael Adamzik
NBNikola Blase
Nikola Blase
Background: Artificial intelligence (AI)–based systems are receiving increasing attention in the health care sector. While the use of AI is well advanced in some medical applications, such as image recognition, it is still in its infancy in others, such as clinical decision support systems (CDSS). Examples of AI-based CDSS can be found in the context of sepsis prediction or antibiotic prescription. Scientific literature indicates that such systems can support physicians in their daily work and lead to improved patient outcomes. Nevertheless, there are various problems and barriers in this context that should be considered. Objective: This study aimed to identify opportunities to optimize AI-based CDSS and their integration into care from the perspective of experts. Methods: Semistructured web-based expert interviews were conducted. Experts representing the perspectives of patients; physicians; caregivers; developers; health insurance representatives; researchers (especially in law and IT); and experts in regulation, market admission and quality management or assurance, and ethics were included. The conversations were recorded and transcribed. Subsequently, a qualitative content analysis was performed. The different approaches to improvement were categorized into groups (“technology,” “data,” “users,” “studies,” “law,” and “general”). These also served as deductive codes. Inductive codes were determined within an internal project workshop. Results: In total, 13 individual and 2 double interviews were conducted with 17 experts. A total of 227 expert statements were included in the analysis. Suggestions were heterogeneous and concerned improvements: (1) in the systems themselves (eg, implementing comprehensive system training involving [future] users; using a comprehensive and high-quality database; considering usability, transparency, and customizability; preventing automation bias through control mechanisms or intelligent design; conducting studies to demonstrate the benefit of the system), (2) on the user side (eg, training [future] physicians could contribute to a more positive attitude and to greater awareness and questioning decision supports suggested by the system and ensuring that the use of the system does not lead to additional work), and (3) in the environment in which the systems are used (eg, increasing the digitalization of the health care system, especially in hospitals; providing transparent public communication about the benefits and risks of AI; providing research funding; clarifying open legal issues, eg, those related to liability; and standardizing and consolidating various approval processes). Conclusions: This study offers several possible strategies for improving AI-based CDSS and their integration into health care. These were found in the areas of “technology,” “data,” “users,” “studies,” “law,” and “general.” Systems, users, and the environment should be taken into account to ensure that the systems are used safely, effectively, and sustainably. Further studies should investigate both the effectiveness of strategies to improve AI-based CDSS and their integration into health care and the accuracy of their match to specific problems. International Registered Report Identifier (IRRID): RR2-10.2196/62704

29 January 2012 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
SSS. U. Sixt
S. U. Sixt
RAR. Alami
R. Alami
JHJ. Hakenbeck
J. Hakenbeck
MAM. Adamzik
M. Adamzik
AKA. Kloß
A. Kloß
JPJ. Peters
J. Peters
There is increasing evidence that proteasomes have a biological role in the extracellular alveolar space, but inflammation could change their composition. We tested whether immunoproteasome protein-containing subpopulations are present in the alveolar space of patients with lung inflammation evoking the acute respiratory distress syndrome (ARDS). Bronchoalveolar lavage (BAL) supernatants and cell pellet lysate from ARDS patients (n=28) and healthy subjects (n=10) were analyzed for the presence of immunoproteasome proteins (LMP2 and LMP7) and proteasome subtypes by western blot, chromatographic purification, and 2D-dimensional gelelectrophoresis. In all ARDS patients but not in healthy subjects LMP7 and LMP2 were observed in BAL supernatants. Proteasomes purified from pooled ARDS BAL supernatant showed an altered enzyme activity ratio. Chromatography revealed a distinct pattern with 7 proteasome subtype peaks in BAL supernatant of ARDS patients that differed from healthy subjects. Total proteasome concentration in BAL supernatant was increased in ARDS (971 ng/mL±1116 versus59±25;P<0.001), and all fluorogenic substrates were hydrolyzed, albeit to a lesser extent, with inhibition by epoxomicin (P=0.0001). Thus, we identified for the first time immunoproteasome proteins and a distinct proteasomal subtype pattern in the alveolar space of ARDS patients, presumably in response to inflammation.

13 July 2024 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
LPLars Palmowski
Lars Palmowski
SLSimone Lindau
Simone Lindau
LHLaura Contreras Henk
Laura Contreras Henk
BMBritta Marko
Britta Marko
AWAndrea Witowski
Andrea Witowski
Tim RahmelTim Rahmel
Tim Rahmel
In sepsis, initial resuscitation with fluids is followed by efforts to achieve a negative fluid balance. However, patients with sepsis-associated acute kidney injury (SA-AKI) often need diuretic or renal replacement therapy (RRT). The dilemma is to predict whether early RRT might be advantageous or diuretics will suffice. Both the Furosemide Stress Test (FST) and measurements of the urinary biomarkers TIMP-2*IGFBP-7, if applied solely, do not provide sufficient guidance. We tested the hypothesis that a combination of two tests, i.e., an upstream FST combined with downstream measurements of urinary TIMP-2*IGFBP-7 concentrations improves the accuracy in predicting RRT necessity. In this prospective, multicenter study 100 patients with sepsis (diagnosed < 48h), AKI stage ≥ 2, and an indication for negative fluid balance were included between 02/2020 and 12/2022. All patients received a standardized FST and urinary biomarkers TIMP-2*IGFBP-7 were serially measured immediately before and up to 12 h after the FST. The primary outcome was the RRT requirement within 7 days after inclusion. 32% (n = 32/99) of SA-AKI patients eventually required RRT within 7 days. With the FST, urine TIMP-2*IGFBP-7 decreased within 2 h from 3.26 ng2/mL2/1000 (IQR: 1.38–5.53) to 2.36 ng2/mL2/1000 (IQR: 1.61–4.87) in RRT and 1.68 ng2/mL2/1000 (IQR: 0.56–2.94) to 0.27 ng2/mL2/1000 (IQR: 0.12–0.89) and non-RRT patients, respectively. While TIMP-2*IGFBP-7 concentrations remained low for up to 12 h in non-RRT patients, we noted a rebound in RRT patients after 6 h. TIMP-2*IGFBP-7 before FST (accuracy 0.66; 95%-CI 0.55–0.78) and the FST itself (accuracy 0.74; 95%-CI: 0.64–0.82) yielded moderate test accuracies in predicting RRT requirement. In contrast, a two-step approach, utilizing FST as an upstream screening tool followed by TIMP-2*IGFBP-7 quantification after 2 h improved predictive accuracy (0.83; 95%-CI 0.74–0.90, p = 0.03) compared to the FST alone, resulting in a positive predictive value of 0.86 (95%-CI 0.64–0.97), and a specificity of 0.96 (95%-CI 0.88–0.99). The combined application of an upstream FST followed by urinary TIMP-2*IGFBP-7 measurements supports highly specific identification of SA-AKI patients requiring RRT. Upcoming interventional trials should elucidate if this high-risk SA-AKI subgroup, identified by our predictive enrichment approach, benefits from an early RRT initiation.

30 January 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
PRPascal Raszke
Pascal Raszke
GGGodwin Denk Giebel
Godwin Denk Giebel
CACarina Abels
Carina Abels
JWJuergen Wasem
Juergen Wasem
MAMichael Adamzik
Michael Adamzik
NBNikola Blase
Nikola Blase
Background: Artificial intelligence (AI)–based clinical decision support systems (CDSS) have been developed for several diseases. However, despite the potential to improve the quality of care and thereby positively impact patient-relevant outcomes, the majority of AI-based CDSS have not been adopted in standard care. Possible reasons for this include barriers in the implementation and a nonuser-oriented development approach, resulting in reduced user acceptance. Objective: This research project has 2 objectives. First, problems and corresponding solutions that hinder or support the development and implementation of AI-based CDSS are identified. Second, the research project aims to increase user acceptance by creating a user-oriented requirement profile, using the example of sepsis. Methods: The research project is based on a multimethod approach combining (1) a scoping review, (2) focus groups with physicians and professional caregivers, and (3) semistructured interviews with relevant stakeholders. The research modules mentioned provide the basis for the development of a (4) survey, including a discrete choice experiment (DCE) with physicians. A minimum of 6667 physicians with expertise in the clinical picture of sepsis are contacted for this purpose. The survey is followed by the development of a requirement profile for AI-based CDSS and the derivation of policy recommendations for action, which are evaluated in a (5) expert roundtable discussion. Results: The multimethod research project started in November 2022. It provides an overview of the barriers and corresponding solutions related to the development and implementation of AI-based CDSS. Using sepsis as an example, a user-oriented requirement profile for AI-based CDSS is developed. The scoping review has been concluded and the qualitative modules have been subjected to analysis. The start of the survey, including the DCE, was at the end of July 2024. Conclusions: The results of the research project represent the first attempt to create a comprehensive user-oriented requirement profile for the development of sepsis-specific AI-based CDSS. In addition, general recommendations are derived, in order to reduce barriers in the development and implementation of AI-based CDSS. The findings of this research project have the potential to facilitate the integration of AI-based CDSS into standard care in the long term. International Registered Report Identifier (IRRID): DERR1-10.2196/62704

12 July 2019 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
HNHartmuth Nowak
Hartmuth Nowak
CWCaroline Weidemann
Caroline Weidemann
SMStefan Martini
Stefan Martini
ZOZoe Anne Oesterreicher
Zoe Anne Oesterreicher
CDChristoph Dorn
Christoph Dorn
Tim RahmelTim Rahmel
Tim Rahmel
Background: For an effective antimicrobial treatment, it is crucial that antibiotics reach sufficient concentrations in plasma and tissue. Currently no data exist regarding moxifloxacin plasma concentrations and exposure levels in tissue under septic conditions. Objectives: To determine the pharmacokinetics of moxifloxacin in plasma and interstitial space fluid over a prolonged period. Patients and methods: Ten septic patients were treated with 400 mg of moxifloxacin once a day; on days 1, 3 and 5 of treatment plasma sampling and microdialysis in the subcutis and muscle of the upper thigh were performed to determine concentrations of moxifloxacin in different compartments. This trial was registered in the German Clinical Trials Register (DRKS, register number DRKS00012985). Results: Mean unbound fraction of moxifloxacin in plasma was 85.5±3.4%. On day 1, Cmax in subcutis and muscle was 2.8±1.8 and 2.5±1.3 mg/L, respectively, AUC was 24.8±15.1 and 21.3±10.5 mg·h/L, respectively, and fAUC0–24/MIC was 100.9±62.9 and 86.5±38.3 h, respectively. Cmax for unbound moxifloxacin in plasma was 3.5±0.9 mg/L, AUC was 23.5±7.5 mg·h/L and fAUC0–24/MIC was 91.6±24.8 h. Key pharmacokinetic parameters on days 3 and 5 showed no significant differences. Clearance was higher than in healthy adults, but tissue concentrations were comparable, most likely due to a lower protein binding. Conclusions: Surprisingly, the first dose already achieved exposure comparable to steady-state conditions. The approved daily dose of 400 mg was adequate in our patient population. Thus, it seems that in septic patients a loading dose on the first day of treatment with moxifloxacin is not required.